Turning Point Therapeutics, an early stage biotech developing tyrosine kinase inhibitors for treating cancer, raised $167 million by offering 9.3 million shares at $18, the high end of the range of $16 to $18.
Turning Point Therapeutics plans to list on the Nasdaq under the symbol TPTX. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as lead managers on the deal.
